A cost-effectiveness model of alternative statins to achieve target LDL-Cholesterol levels

International Journal of Clinical Practice

Volumn 55, Issue 4, 2001, Pages 243-249

  Maclaine, Gdh ^a   Patel, H ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ARTICLE; BUDGET; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG TARGETING; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; ISCHEMIC HEART DISEASE; MODEL; PRIORITY JOURNAL; TITRIMETRY; TREATMENT OUTCOME;

EID: 0034981172     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2001.tb11027.x     Document Type: Article

References (30)

1. NHS Centre for Reviews and Dissemination. Cholesterol and coronary heart disease screening and treatment. Effective Health Care Bull 1998; 4(1): 1-16.
2. Office of Health Economics. Compendium of health statistics. London: Office of Health Economics, 1999.
3. Department of Health. The health of the nation: a strategy for health in England. London: HMSO, 1992.
4. British Heart Foundation. Coronary heart disease statistics: economics supplement. London: British Heart Foundation, 1998.
5. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Summary of the second report on the national cholesterol education program (NCEP). JAMA 1993; 269: 3015-3023.
6. Wood D, Durrington P, Mclnnes G et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80(suppl2): S1-S29.
7. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the Curves Study). Am J Cardiol 1998:81: 582-587.
8. Stein E, Schopen U.Catagay M. A pooled efficacy analysis of cerivastatin in the treatment of primary hyperlipidaemia. Clin Drug Invest 1999; 18(6): 433-444.
9. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
10. Shepherd J, Cobbe S, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333: 1301-1307.
11. Johnsson B, Johanneson M, Kjekshus J et al. Cost-effectiveness of cholesterol-lowering: results from the Simvastatin Survival Study. Eur Heart J 1996; 17: 1001-1007.
12. Caro J, Klittich W, McGuire A et al. The West of Scotland Coronary Prevention Study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577-1582.
13. Pickin D, McCabe C. Ramsay L et al. Cost-effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999; 82: 325-332.
14. Haq I, Ramsay L, Pickin D et al. Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sei 1996; 91: 399-413.
15. Baxter C, Jones R, Corr L. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. BMJ 1998; 317: 1123-1135.
16. Marceilno J, Feingold K. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100: 605-610.
17. Schechtman G, Hiatt J. Drug therapy for hypercholesterolaemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996: 100: 197-204.
18. LaRosa JC. Unresolved issues: unanswered questions. Ear Heart J 1999; l(supplj): J18-J23.
19. North of England Evidence-Based Guidelines Development Project. Primary care management of secondary prophylaxis for patients who have experienced myocardial infarction: drug treatment, cardiac rehabilitation and dietary manipulation. Evidence-based Clinical Practice Guideline. 2000.
20. Smith DG, Leslie S, Szucs T et al. Cost of treating to a modified Atherosclerosis Society LDL-C target: comparison of atorvastatin with fluvastatin. pravastatin and simvastatin. din Drug Invest 1999; 17(3): 185-193.
21. Neil H, Fowler G, Patel H et al. An assessment of the efficacy of atorvastatin in achieving LDL cholesterol target levels in patients with coronary heart disease: a general practice study. Int J Clin Pract 1999; 53(6): 422426.
22. Hilleman D, Phillips J, Pickin D et al. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolaemia. din Ther 1999; 21(3): 536-562.
23. Öse L, Kastelein JJP, Scott R et al. Efficacy and six month safety of simvastatin 80 mg/day: results from the Worldwide Simvastatin Expanded Dose Program (WSEDP). Nutr Metab Cardiovasc Dis 1998; 8: 135-143.
24. Gould A, Rossouw J, Stantanello N et al. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation 1995; 91: 2271-2282.
25. Gould A, Rossouw J. Stantanello N et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97: 946-952.
26. ASPIRE Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease. ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75: 334-342.
27. EUROASPIRE Study Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997: 18: 1569-1582.
28. Hobbs FOR, Erhardt L. Reassessing European Attitudes about Cardiovascular Treatment (REACT): physicians' survey. Eur Heart J 2000: 21(suppl): 477.
29. Huedebert GR, Van Ruiswyk J, Hiatt J et al. Combination therapy for hypercholesterolaemia: the trade-off between cost and simplicity. Arch Intern Med 1993; 153: 1828-1837.
30. Netten A, Dennett J, Knight J. Unit costs of health and .social care. University of Kent, Canterbury: Personal Social Services Research Unit. 1999.